

β -arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation

Bastian Czogalla, Alexandra Partenheimer, Udo Jeschke, Viktoria von Schönfeldt, Doris Mayr, Sven Mahner, Alexander Burges, Manuela Simoni, Beatrice Melli, Riccardo Benevelli, et al.

▶ To cite this version:

Bastian Czogalla, Alexandra Partenheimer, Udo Jeschke, Viktoria von Schönfeldt, Doris Mayr, et al.. β -arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation. Frontiers in Endocrinology, 2020, 11, pp.1-12. 10.3389/fendo.2020.554733 . hal-03151063

HAL Id: hal-03151063 https://hal.inrae.fr/hal-03151063

Submitted on 24 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License





β-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation

Bastian Czogalla^{1*†}, Alexandra Partenheimer^{1†}, Udo Jeschke^{1,2}, Viktoria von Schönfeldt¹, Doris Mayr³, Sven Mahner¹, Alexander Burges¹, Manuela Simoni^{4,5,6,7}, Beatrice Melli⁴, Riccardo Benevelli⁴, Sara Bertini⁴, Livio Casarini^{4,5‡} and Fabian Trillsch^{1‡}

OPEN ACCESS

Edited by:

Jianfeng Liu, Huazhong University of Science and Technology, China

Reviewed by:

Prathibha Ranganathan, Centre for Human Genetics (CHG), India Francesca Lovat, The Ohio State University, United States

*Correspondence:

Bastian Czogalla bastian.czogalla@ med.uni-muenchen.de

[†]These authors share first authorship

[‡]These authors share senior authorship

Specialty section:

This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology

Received: 22 April 2020 Accepted: 12 August 2020 Published: 18 September 2020

Citation:

Czogalla B, Partenheimer A, Jeschke U, von Schönfeldt V, Mayr D, Mahner S, Burges A, Simoni M, Melli B, Benevelli R, Bertini S, Casarini L and Trillsch F (2020) β-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation. Front. Endocrinol. 11:554733. doi: 10.3389/fendo.2020.554733 ¹ Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany, ² Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany, ³ Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany, ⁴ Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁵ Center for Genomic Research, University of Modena and Reggio Emilia, Modena, Italy, ⁶ Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria, Modena, Italy, ⁷ PRC, INRA, CNRS, IFCE, Université de Tours, Nouzilly, France

Establishing reliable prognostic factors as well as specific targets for new therapeutic approaches is an urgent requirement in advanced ovarian cancer. For several tumor entities, the ubiquitously spread scaffold protein β-arrestin 2, a multifunctional scaffold protein regulating signal transduction and internalization of activated G protein-coupled receptors (GPCRs), has been considered with rising interest for carcinogenesis. Therefore, we aimed to elucidate the prognostic impact of β -arrestin 2 and its functional role in ovarian cancer. β-arrestin 2 expression was analyzed in a subset of 156 samples of ovarian cancer patients by immunohistochemistry. Cytoplasmic expression levels were correlated with clinical as well as pathological characteristics and with prognosis. The biologic impact of β-arrestin 2 on cell proliferation and survival was evaluated, in vitro. Following transient transfection by increasing concentrations of plasmid encoding β-arrestin 2, different cell lines were evaluated in cell viability and death. β-arrestin 2 was detected in all histological ovarian cancer subtypes with highest intensity in clear cell histology. High β-arrestin 2 expression levels correlated with high-grade serous histology and the expression of the gonadotropin receptors FSHR and LHCGR, as well as the membrane estrogen receptor GPER and hCG β . Higher cytoplasmic β -arrestin 2 expression was associated with a significantly impaired prognosis (median 29.88 vs. 50.64 months; P = 0.025). Clinical data were confirmed in transfected HEK293 cells, human immortalized granulosa cell line (hGL5) and the ovarian cancer cell line A2780 in vitro, where the induction of β -arrestin 2 cDNA expression enhanced cell viability, while the depletion of the molecule by siRNA resulted in cell death. Reflecting the role of β -arrestin 2 in modulating GPCR-induced proliferative and anti-apoptotic signals, we propose β -arrestin 2 as an important prognostic factor and also as a promising target for new therapeutic approaches in advanced ovarian cancer.

Keywords: β-arrestin 2, ovarian cancer, immunohistochemistry, survival analysis, G protein-coupled receptor, *in vitro* analyses

INTRODUCTION

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy and is considered the fifth leading cause of death among women (1), mainly due to late diagnosis in advanced tumor stage leading to overall poor prognosis. Lack of inadequate screening methods and rising resistances toward chemotherapy over the clinical course further contribute to the relatively low 5-years survival at around 45% (1, 2). Standard treatment for advanced EOC consists of primary cytoreductive surgery, followed by platinum-based combination chemotherapy followed by targeted therapies like the anti-angiogenic antibody bevacizumab or PARP inhibitors. To date, the most reliable prognostic factors include volume of post-operative residual disease, tumor stage diagnosed according to the International Federation of Gynecology and Obstetrics (FIGO) staging system, patient's age and histology (2-7). EOCs are classified into four histological subtypes: serous, mucinous, endometrioid, and clearcell, which vary in terms of phenotype, etiology and molecular background (8). Taking the heterogeneity of ovarian cancer into account appears crucial for developing new prognostic and therapeutic strategies.

β-arrestin 2 is a multifunctional scaffold protein regulating signal transduction and internalization of activated G proteincoupled receptors (GPCRs) like follicle-stimulating hormone receptor (FSHR) and luteinizing hormone/choriogonadotropin receptor (LHCGR) by promoting clathrin-dependent endocytosis (9). The β-arrestin family is a known activator of signaling pathways involved in tumorgenesis (10–12) and proliferation of certain tumor entities (13–17), including ovarian cancer (18). Functional association between FSHR/LHCGR and β-arrestin in granulosa cells could be demonstrated after gonadotropin treatment *in vitro* (19, 20). In immortalized ovarian cell lines, β-arrestin 2 triggers the activation of FSHinduced mitogen-activated protein (MAP) kinase signaling cascades linked to anti-apoptotic and proliferative events (21).

In this study, we aimed to evaluate the possible prognostic impact of β -arrestin 2 on clinical course of ovarian cancer. The role of β -arrestin 2 in modulating cell viability and survival was elucidated by functional analyses *in vitro*, suggesting new therapeutic approaches in ovarian cancer.

MATERIALS AND METHODS

Patients and Specimens

156 ovarian cancer samples of patients that underwent surgery between 1990 and 2002 at the Department of Obstetrics and Gynecology, Ludwig Maximilian University in Munich, Germany, were analyzed (**Table 1**). The clinical data were received from the patient's charts, whereas the follow-up data from the Munich Cancer Registry (MCR). Only patients with a clear diagnosis of ovarian cancer and were included in this study, while benign tumors, just as borderline tumors were excluded. These patients had no history of previous or secondary cancers. Also, none of the patients had neoadjuvant chemotherapy. After the samples had been formalin-fixed and paraffin-embedded (FFPE), they were evaluated by a specialized pathologist at the TABLE 1 | Patient characteristics.

HISTOLOGY Serous 110 70.5 Clear cell 12 7.7 Endometrioid 21 13.5 Mucinous 13 8.3 LYMPH NODE 90.1 pNX 61 39.1 pNV 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS 90.2 pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 24 Low 24 23.0 High 80 77.0 ENDOMETRIOID 6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 0 G1 6 50.0 G3 9 100 FIGO 10 I 35 23.1 II 103 68.2 IV 3 2.0	Parameters	Ν	Percentage (%)																								
Serous 110 70.5 Clear cell 12 7.7 Endometrioid 21 13.5 Mucinous 13 8.3 LYMPH NODE 13 8.3 LYMPH NODE 90 91 91 pNX 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS 96.2 pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 24 23.0 Low 24 23.0 High 80 77.0 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 0 0 G1 6 50.0 G2 6 50.0 G3 9 100 FIGO 10 6.6 III 103 68.2 IV<	HISTOLOGY																										
Clear cell 12 7.7 Endometrioid 21 13.5 Mucinous 13 8.3 LYMPH NODE 9 9.1 pNX 61 39.1 pNQ 43 27.6 pN1 52 33.3 DISTANT METASTASIS 3.8 pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 24 23.0 Low 24 23.0 High 80 77.0 ENDOMETRIOID 700 700 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 0 0 G1 6 50.0 G2 6 50.0 G3 9 100 FIGO 100 6.6 II 103 6.8.2 IV 3 2.0 AGE 2.0 AGE 2.0 AGE 2.0 AGE 2.0 AGE 53.2 <60 years	Serous	110	70.5																								
Endometrioid 21 13.5 Mucinous 13 8.3 LYMPH NODE 9 9 pNX 61 39.1 pN0 43 27.6 pN1 52 33.8 DISTANT METASTASIS 96.2 pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 24 23.0 Low 24 23.0 High 80 77.0 ENDOMETRIOID 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 0 0 G1 6 50.0 G2 6 50.0 G3 0 0 G3 9 100 FIGO 10 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 3 <tr td=""> 50.2 <t< td=""><td>Clear cell</td><td>12</td><td>7.7</td></t<></tr> <tr><td>Mucinous 13 8.3 LYMPH NODE 39.1 39.1 pNX 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 FIGO I 35 23.1 I 103 68.2 IV 3 2.0 <</td><td>Endometrioid</td><td>21</td><td>13.5</td></tr> <tr><td>LYMPH NODE pNX 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS 96.2 pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 150 96.2 Low 24 23.0 High 80 77.0 ENDOMETRIOID 10 6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 100 6 G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 FIGO 100 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 3.2 S60 years 73 46.8</td><td>Mucinous</td><td>13</td><td>8.3</td></tr> <tr><td>pNX6139.1pN04327.6pN1523.3DISTANT METASTASISpM0/X15096.2pM163.8GRADING SEROUSLow2423.0High8077.0ENDOMETRIOIDG1631.6G2526.3G3842.1MUCINOUSG1650.0G2650.0G300CLEAR CELLG39100FIGO106.6II10368.2IV32.0ACE260 years8353.2>60 years7346.8</td><td>LYMPH NODE</td><td></td><td></td></tr> <tr><td>pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 IV 3 2.0 AGE ≤60 years 83 53.2 >60 years 83 53.2</td><td>pNX</td><td>61</td><td>39.1</td></tr> <tr><td>pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G3 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 I 104 6.6 II 103 68.2 I 105 65.2 I 105</td><td>pN0</td><td>43</td><td>27.6</td></tr> <tr><td>DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 24 23.0 Low 24 23.0 High 80 77.0 ENDOMETRIOID 0 6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 0 0 G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 G3 9 100 FIGO 10 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 3 <60 years</td> 83 53.2 <60 years</tr>	Clear cell	12	7.7	Mucinous 13 8.3 LYMPH NODE 39.1 39.1 pNX 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 FIGO I 35 23.1 I 103 68.2 IV 3 2.0 <	Endometrioid	21	13.5	LYMPH NODE pNX 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS 96.2 pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 150 96.2 Low 24 23.0 High 80 77.0 ENDOMETRIOID 10 6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 100 6 G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 FIGO 100 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 3.2 S60 years 73 46.8	Mucinous	13	8.3	pNX6139.1pN04327.6pN1523.3DISTANT METASTASISpM0/X15096.2pM163.8GRADING SEROUSLow2423.0High8077.0ENDOMETRIOIDG1631.6G2526.3G3842.1MUCINOUSG1650.0G2650.0G300CLEAR CELLG39100FIGO106.6II10368.2IV32.0ACE260 years8353.2>60 years7346.8	LYMPH NODE			pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 IV 3 2.0 AGE ≤60 years 83 53.2 >60 years 83 53.2	pNX	61	39.1	pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G3 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 I 104 6.6 II 103 68.2 I 105 65.2 I 105	pN0	43	27.6	DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 24 23.0 Low 24 23.0 High 80 77.0 ENDOMETRIOID 0 6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 0 0 G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 G3 9 100 FIGO 10 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 3 <60 years	pN1	52	33.3
Clear cell	12	7.7																									
Mucinous 13 8.3 LYMPH NODE 39.1 39.1 pNX 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 FIGO I 35 23.1 I 103 68.2 IV 3 2.0 <	Endometrioid	21	13.5																								
LYMPH NODE pNX 61 39.1 pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS 96.2 pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 150 96.2 Low 24 23.0 High 80 77.0 ENDOMETRIOID 10 6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 100 6 G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 FIGO 100 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 3.2 S60 years 73 46.8	Mucinous	13	8.3																								
pNX6139.1pN04327.6pN1523.3DISTANT METASTASISpM0/X15096.2pM163.8GRADING SEROUSLow2423.0High8077.0ENDOMETRIOIDG1631.6G2526.3G3842.1MUCINOUSG1650.0G2650.0G300CLEAR CELLG39100FIGO106.6II10368.2IV32.0ACE260 years8353.2>60 years7346.8	LYMPH NODE																										
pN0 43 27.6 pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 IV 3 2.0 AGE ≤60 years 83 53.2 >60 years 83 53.2	pNX	61	39.1																								
pN1 52 33.3 DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G3 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 I 104 6.6 II 103 68.2 I 105 65.2 I 105	pN0	43	27.6																								
DISTANT METASTASIS pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS 24 23.0 Low 24 23.0 High 80 77.0 ENDOMETRIOID 0 6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 0 0 G1 6 50.0 G2 6 50.0 G3 0 0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 G3 9 100 FIGO 10 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 3 <60 years																											
pM0/X 150 96.2 pM1 6 3.8 GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS G1 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 V 3 2.0 AGE ≤60 years 83 53.2	DISTANT METASTASIS	;																									
pM1 6 3.8 GRADING SEROUS 23.0 Low 24 23.0 High 80 77.0 ENDOMETRIOID 0 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 10 G1 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 I 35 23.1 I 103 68.2 IV 3 2.0 AGE 103 68.2 <	pM0/X	150	96.2																								
GRADING SEROUS Low 24 23.0 High 80 77.0 ENDOMETRIOID 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 1 6 G1 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 I 35 23.1 II 103 66.2 IV 3 2.0 AGE 2.0 46.8	pM1	6	3.8																								
Low 24 23.0 High 80 77.0 ENDOMETRIOID 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 42.1 G1 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 FIGO 100 6.6 II 35 23.1 I 10 6.6 III 103 68.2 IV 3 2.0 AGE 53.2 53.2 <60 years	GRADING SEROUS																										
High 80 77.0 ENDOMETRIOID 6 31.6 G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 10 G1 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 FIGO 100 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 46.8 >60 years 83 53.2 >60 years 73 46.8	Low	24	23.0																								
ENDOMETRIOID G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 42.1 G1 6 50.0 G2 6 50.0 G2 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 FIGO 100 I 35 23.1 I 10 6.6 III 103 68.2 IV 3 2.0 AGE ≤60 years 83 53.2 >60 years 73 46.8	High	80	77.0																								
G1 6 31.6 G2 5 26.3 G3 8 42.1 MUCINOUS 7 G1 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 7 100 FIGO 100 6.6 II 103 68.2 IV 3 2.0 AGE 53.2 ≤60 years 83 53.2 >60 years 73 46.8	ENDOMETRIOID																										
G2 5 26.3 G3 8 42.1 MUCINOUS 5 50.0 G1 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 G3 9 100 FIGO 10 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 ≤60 years 83 53.2 >60 years 73 46.8	G1	6	31.6																								
G3 8 42.1 MUCINOUS 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 G3 9 100 FIGO 10 6.6 II 103 68.2 IV 3 2.0 AGE 53.2 53.2 >60 years 73 46.8	G2	5	26.3																								
MUCINOUS G1 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL 0 0 G3 9 100 FIGO 100 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 2.0 >60 years 83 53.2 >60 years 73 46.8	G3	8	42.1																								
G1 6 50.0 G2 6 50.0 G3 0 0 CLEAR CELL G3 9 100 FIGO 73 23.1 I 10 6.6 II 103 68.2 IV 3 2.0 AGE 2.0 ≤60 years 83 53.2 >60 years 73 46.8	MUCINOUS																										
G2 6 50.0 G3 0 0 CLEAR CELL G3 9 100 FIGO I 35 23.1 I 10 6.6 II 103 68.2 IV 3 2.0 AGE ≤60 years 83 53.2 >60 years 73 46.8	G1	6	50.0																								
G3 0 0 CLEAR CELL G3 9 100 FIGO I 10 35 23.1 II 10 6.6 III 103 68.2 IV 3 2.0 AGE ≤60 years 83 53.2 >60 years 73 46.8	G2	6	50.0																								
CLEAR CELL G3 9 100 FIGO 35 23.1 I 10 6.6 II 103 68.2 IV 3 2.0 AGE 53.2 560 years >60 years 73 46.8	G3	0	0																								
G3 9 100 FIGO I 35 23.1 II 10 6.6 III 103 68.2 IV 3 2.0 AGE ≤60 years 83 53.2 >60 years 73 46.8	CLEAR CELL																										
FIGO I 35 23.1 II 10 6.6 III 103 68.2 IV 3 2.0 AGE 2 2 >60 years 83 53.2 >60 years 73 46.8	G3	9	100																								
35 23.1 II 10 6.6 III 103 68.2 IV 3 2.0 AGE 53.2 >60 years 73 46.8	FIGO																										
II 10 6.6 III 103 68.2 IV 3 2.0 AGE 560 years 83 53.2 >60 years 73 46.8	I	35	23.1																								
III 103 68.2 IV 3 2.0 AGE 53.2 >60 years 73 46.8	II	10	6.6																								
Ⅳ 3 2.0 AGE 2 60 years 83 53.2 >60 years 73 46.8	Ш	103	68.2																								
AGE ≤60 years 83 53.2 >60 years 73 46.8	IV	3	2.0																								
≤60 years 83 53.2 >60 years 73 46.8	AGE																										
>60 years 73 46.8	≤60 years	83	53.2																								
	>60 years	73	46.8																								

department of Pathology, Ludwig Maximilian University, who classified them into histological subtypes [serous (n = 110), endometrioid (n = 21), mucinous (n = 13), clear-cell (n = 12)] and rated the tumor grading. The serous ovarian cancer samples were divided into low and high grading. Endometrioid ovarian cancer was graded according to G1–G3. For the mucinous carcinoma, there is no WHO classification; however, the subtype is often classified into G1–G3. The clear cell cancer was always categorized as G3. Staging was performed using the FIGO (WHO) and TNM classification. I (n = 35), II (n = 10,) III (n = 103), and IV (n = 3). Data on primary tumor extension was available in 155 cases: T1 (n = 40), T2 (n = 18), T3 (n = 93), T4 (n = 4), and on lymph node involvement in 95 cases: N0 (n = 43), N1 (n = 52). In nine cases available was the data on distant metastasis: M0 (n = 3), M1 (n = 6).

Ethical Approval

This study was approved by the Ethics Committee of the Ludwig-Maximilians-University, Munich, Germany (approval number 227-09 and 18-392). All tissue samples used for this study were obtained from leftover material from the archives of LMU Munich, Department Gynecology and Obstetrics, Ludwig-Maximilians-University, Munich, Germany, initially used for pathological diagnostics. The diagnostic procedures were completed before the current study was performed. During all experimental and statistical analysis, the observers were fully blinded to patient's data. All experiments were performed according to the standards of the Declaration of Helsinki (1975). As per declaration of our ethics committee no written informed consent of the participants or permission to publish is needed given the circumstances described above.

Immunohistochemistry

The formalin-fixed and paraffin-embedded ovarian cancer tissue samples were dewaxed in xylene for 20 min, before adding 100% ethanol to completely remove the Xylol. Unspecific color responses were avoided by blocking the endogenous peroxidase with 3% H₂O₂ in methanol (3 ml 30% H₂O₂ + 97 ml methanol), followed by rehydrating it in 70%, then 50% ethanol. Afterwards the slides were placed in a pressure cooker for 10 min, using sodium citrate buffer (pH = 6), made from 0.1 M citric acid and 0.1 M sodium citrate). After cooling down, this was followed by washing the samples first in distilled water, then in phosphate buffered saline (PBS) twice. After preprocessing, the slides were incubated in a blocking solution (ZytoChem Plus HRP Polymer System, Berlin, Germany, POLHRP-100) for 5 min to prevent an unspecific staining reaction. This was followed by a 16h incubation overnight at 4°C with the primary antibodies: anti-β-arrestin 2, rabbit IgG, polyclonal, Abcam, ab151774 at a 1:1,500 dilution; anti-FSHR, rabbit IgG, polyclonal, Novus Biologicals, NLS2231 at a 1:100 dilution, anti-LHCGR, rabbit IgG, polyclonal, Acris, SP4594P at a 1:800 dilution; anti-GPER, rabbit IgG, polyclonal, Lifespan Biosciences, LS92467 at a 1:600 dilution and anti-hCGB, rabbit IgG, polyclonal, Dako, A-0231 at a 1:300 dilution-then washed in PBS twice. Next step was the application of reagent 2 (ZytoChem Plus HRP Polymer System, Berlin, Germany, POLHRP-100), consisting of a corresponding biotinylated secondary anti-rabbit IgG antibody and the associated avidin-biotin-peroxidase complex, for 20 min. For the visualization reaction 3,3 Diaminobenzidine (DAB) and a substrate buffer (Liquid DAB and Substrate Chromogen System, Dako, Munich, Germany, K3468) was used for 30 min, followed by distilled water, to stop the reaction. After counterstaining the slides with Mayer's acidic hematoxylin (Waldeck-Chroma, Münster, Germany, catalog-number 2E-038) for 2 min, they were dehydrated in an ascending series of alcohol (70, 96, 100%), brightened by adding xylol and then covered. Negative and positive controls were used to assess the specificity of the immunoreactions. Negative controls (colored in blue) were performed in kidney, placental and uterine tissue by replacement of the primary antibodies by species-specific (rabbit) isotype control antibodies (Dako, Glostrup, Denmark). For positive controls, placental and kidney tissues were used.

Staining Evaluation

All EOC specimens were examined with a Leitz photomicroscope (Wetzlar, Germany) and specific β-arrestin 2 immunohistochemically staining reaction was observed in the cytoplasm of the cells. The intensity and distribution pattern of β -arrestin 2 staining was rated using the semi-quantitative immunoreactive score (IR score, Remmele's score). To obtain the IR score result, the optional staining intensity $(0 = n_0, 1 = weak)$ 2 =moderate, and 3 =strong staining) and the percentage of positive stained cells (0 = no staining, 1 = <10% of the cells, 2 = 11-50% of the cells, 3 = 51-80% of the cells and 4 = >81%) were multiplied. Cut-off points for the IR scores were selected for the β -arrestin 2 staining considering the distribution pattern of IR scores in the collective. β-arrestin 2 staining was regarded as low with IRS 0–3 and as high with IRS \geq 4. Renal biopsies from patients with different ARRB2 expression levels served as positive and negative control staining (22) (Figures 1E,F).

Cell Lines and Transfection Protocol

The immortalized human granulosa (hGL5) cell line of ovarian origin (23), the human embryonic kidney (HEK293) and the ovarian carcinoma (A2780) cell lines were used for in vitro experiments. Cells were cultured and handled as previously described (21, 24-26). hGL5 cells culture medium was DMEM/F12 supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA), 100 IU/mL penicillin and 50 µg/mL streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) and 2% ITS + Premix Universal Culture Supplement (#354352; Corning Incorporated, Corning, NY, USA). The HEK293 cell line was cultured in DMEM additioned of 10% FBS, 2 mM L-glutamine, 100 IU/mL penicillin and 50 µg/mL streptomycin. The A2780 cell line served as a model of ovarian cancer and was cultured in RPMI1640 medium (Sigma-Aldrich) additioned of 10% FBS, 1% Hepes (Sigma-Aldrich), 2 mM L-glutamine, 100 IU/mL penicillin and 50 µg/mL streptomycin. Cell lines were maintained in an incubator at 37°C and 5% CO₂.

The transfection protocol was described previously (25–28). Briefly, 3.5×10^4 cells were transiently transfected in a 96well plate using increasing amount (range: 0–200 ng/well) of β -arrestin 2-encoding pcDNA3.1 plasmid (29) or commercial siRNA probes against β -arrestin 2 (#14387; Life-Technologies, Carlsbad, CA, USA) (21), using an electroporator (Gene Pulser MXcell; Bio-Rad Laboratories Inc., Hercules, CA, USA) in accordance with established protocol and settings (21, 30). Control probes without specific target mRNAs were loaded for achieving equal amount of siRNA among wells.

Western Blot Analysis and Antibodies

Overexpression and knock-down of β -arrestin 2 and procaspase 3 were evaluated by Western blotting, as previously described (21, 24). Briefly, transfected cells were seeded in 24well plates (1 × 10⁵ cells/well) and cultured 48 h before to be lysed using 4°C RIPA buffer. β -arrestin 2 and pro-caspase 3 were evaluated by 12% SDS-page and Western blotting, using specific antibodies (#3857, Cell Signaling Technology Inc., Danvers, MA, USA; #MA1-91637, Thermo-Fisher Scientific, respectively). β -actin signals served as loading controls and were detected using a horseradish peroxidase (HRP)-conjugated specific antibody (#A3854; Sigma-Aldrich). Signals were revealed by ECL chemiluminescent compound (GE HealthCare), after incubation of the membranes with a secondary anti-rabbit HRP-conjugated antibody (#NA9340V; GE HealthCare), except for β -actin. Western blotting signals were acquired by the Quantity One analysis software (Bio-Rad Laboratories Inc., Hercules, CA, USA).

Analysis of Cell Viability and Death

hGLC, HEK293, and A2780 cells were seeded in 96-well plates $(1 \times 10^4 \text{ cells/well})$ before viability assessment the by MTT colorimetric assay (31), using a previously validated protocol (21, 30). The absorbance was detected by a Victor3 plate reader (Perkin Elmer Inc., Waltham, MA, USA). A measure of death cells was obtained by incubating samples 30 min with propidium iodide (32). Cells were washed twice by PBS before excitation and light emission detection by a CLARIOstar microplate reader (BMG LabTech, Ortenberg, Germany), following the manufacturer's protocol. Data were represented as box and whiskers plots in a graph, as a measure of cell viability, and control of protein amount per well was performed by Bradford assay.

Statistical Analysis

IBM SPSS Statistics, version 25.0 (IBM Corporation, Armonk, NY, USA) was used for collecting and analyzing all the data for statistical significance. Overall-survival was compared with Kaplan-Meier curves and log-rank testing was used to detect differences in patients' overall survival times. The Spearman correlation coefficient (cc) was used for detecting correlations between immunohistochemical staining outcomes. For multivariate analyses, the cox regression was performed. Results obtained from cell lines were analyzed by D'Agostino and Pearson normality test before applying the Kruskal-Wallis test together with Dunn's correction for multiple comparisons, using the GraphPad Prism 6.0 software (GraphPad Software Inc., La Jolla, CA, USA). For all analysis a *P*-value of <0.05 was considered to be statistically significant.

RESULTS

β-arrestin 2 Expression and the Correlation to Clinical and Pathological Characteristics

The clinicopathologic characteristics of the analyzed ovarian cancer patients are listed in **Table 1**. 104 (67%) out of 156 ovarian cancer specimens showed positive cytoplasmic β -arrestin 2 expression. The median immunoreactive score (IRS) of cytoplasm staining was 2 (with a range of 0–12). Clear cell histology exhibited the strongest β -arrestin 2 staining (Kruskal-Wallis test; p = 0.01) when compared with different histological subtypes (**Figures 1A–D**).

Representative staining of benign ovarian and fallopian tube tissue show positive results in epithelial cells, granulosa cells and theca cells. The ovarian and fallopian tube stroma did not show a β -arrestin 2 staining (**Figures 2A,B**).

We analyzed the correlation between β -arrestin 2 and clinicopathological data, such as histology, grading, and FIGO classification (**Table 2**). A positive correlation was observed between high β -arrestin 2 expression and high-grade serous histology (Spearman's correlation analysis; p = 0.041; cc = 0.169). Moreover, no other correlations were observed.

β-arrestin 2 Correlates With Gonadotropin Receptors Expression

We then analyzed the correlation between β -arrestin 2 expression and other parameters previously examined (33–37) in the same ovarian cancer cohort (**Table 3**). A positive correlation was detected to the expression of the gonadotropin receptors FSHR (p = 0.029; cc = 0.183) and LHCGR (p = 0.001; cc = 0.284), the G protein-coupled membrane estrogen receptor GPER (p = 0.0009; cc = 0.215) as well as with the choriogonadotropin beta subunit (hCG β) (p < 0.001; cc = 0.36). Representative stainings of the correlated parameters are shown in **Supplementary Figure 1**.

High β-arrestin 2 Expression Is Associated With Impaired Overall Survival

Age of the patient cohort was 58.7 \pm 31.4 years (median \pm standard deviation, SD; n = 156) with a range of 31–88 years. The overall survival of the EOC patients was 34.4 \pm 57.8 months (median \pm SD; n = 156). High β -arrestin 2 expression (IRS 4–12) is associated with shorter overall survival. As depicted on the Kaplan-Meier curve, higher cytoplasmic β -arrestin 2 expression correlates with a significantly impaired prognosis (**Figure 3**; 50.64 vs. 29.88 months, median; p = 0.025).

Clinicopathological Parameters as Independent Prognostic Factors

A multivariate cox-regression analysis was performed to detect which parameters were independent prognostic factors for overall survival in the present cohort. In this analysis, patients' age (p = 0.014) and FIGO stage (p < 0.001) were independent factors for overall survival. High β -arrestin 2 (p = 0.152), however, was not confirmed as an independent factor of prognostic independence (**Table 4**).

Effects of β -arrestin 2 Overexpression and Depletion on Cell Viability

Since β -arrestin 2 expression levels were found to correlate with overall survival of ovarian cancer patients, the impact of the molecule on cell proliferation and survival was evaluated, *in vitro*. Cell viability and death are represented by box and whiskers plots (**Figure 4**).

Western blot analysis demonstrated that β -arrestin 2 expression levels increase together with the amount of cDNA encoding the molecule, in the HEK293, hGL5 and A2780 cell lines (**Figure 4A**). We found increased viability of all cell models overexpressing β -arrestin 2, compared to mock-transfected cells used as controls (**Figures 4B-D**; Kruskal-Wallis test; p < 0.01; n = 8). Moreover, highest levels of cell viability corresponded to the highest amount of plasmid transfected. These results are corroborated by data from propidium iodide-stained HEK293



and A2780 cells overexpressing β -arrestin 2, indicating that the least cell death occurs with the highest amounts of β -arrestin 2-encoding plasmid transfected (**Figures 4E–G**; Kruskal-Wallis test; p < 0.01; n = 8). However, data from transfected hGL5 cells did not reveal any association between β -arrestin 2 expression and cell death (**Figure 4F**; Kruskal-Wallis test; $p \ge 0.05$; n = 8).

Since a positive correlation between β -arrestin 2 expression and cell viability was found (**Figure 4**), control experiments were performed by evaluating the cell viability and death of cells maintained under β -arrestin 2 depletion, *in vitro*. Therefore, HEK293, hGL5, and A2780 cells were treated by increasing concentrations of siRNA probes silencing the endogenous molecule, then MTT assay and propidium iodide staining were performed (**Figure 5**).

The viability of all the cell lines is significantly reduced upon β -arrestin 2 depletion (**Figures 5A–C**; Kruskal-Wallis test; p < 0.05; n = 8). These data are reflected by increased propidium iodide signals occurring together with increasing amounts of siRNAs, in HEK293 cells (**Figure 5D**; Kruskal-Wallis test; p < 0.05; n = 8), while similar signals were found between siRNA-



FIGURE 2 | Detection of β -arrestin 2 with immunohistochemistry in benign ovary and fallopian tube. Detection of β -arrestin 2 with immunohistochemistry in benign ovary (A) and fallopian tube (B). Positive β -arrestin 2 staining was observed in epithelial cells, granulosa cells and theca cells. The ovarian and fallopian tube stroma did not show a β -arrestin 2 staining. Arrows demonstrate representatively β -arrestin 2 stained cells. Images representative of three independent experiments.

TABLE 2 | Correlation analysis between $\beta\text{-arrestin}\ 2$ expression and clinicopathological data.

Variable	Р	Correlation coefficient
Histology	0.075	-0.083
FIGO stage	0.673	0.086
Age	0.206	0.105
GRADING		
Clear cell, endometrioid, and mucinous (G1-G3)	0.520	-0.088
Serous-low grading	0.052	-0.160
Serous-high grading	0.041*	0.169

Clinicopathologic data and β -arrestin 2 expression were correlated to each other using Spearman's correlation analysis. Significant correlations are indicated by asterisks (*p < 0.05). p, two-tailed significance.

and mock-treated hGL5 and A2780 cells (**Figures 5E,F**; Kruskal-Wallis test; $p \ge 0.05$; n = 8). Western blotting analysis confirmed the siRNA-dependence of β -arrestin 2 silencing, which is linked to pro-caspase 3 cleavage in all the cell lines (**Figure 5G**).

DISCUSSION

Our study revealed for the first time that β -arrestin 2 expression significantly correlates with impaired overall survival of ovarian cancer patients and these results are consistent with the proliferative role of β -arrestin 2 demonstrated *in vitro*. β arrestins are known to act as scaffold proteins controlling multiple cellular functions, such as MAP kinase signaling, GPCR trafficking and transcriptional modulations (38, 39). Several studies demonstrated that β -arrestins are involved in carcinogenesis of the ovary (11, 18) and other types of cancer (10, 12–17). The relevance of the GPCR/ β -arrestin pathway in ovarian cancer cells is demonstrated by the finding that endothelin-1 receptor/ β -arrestin complex activates beta-catenin signaling pathways with impact on carcinogenesis and metastatic progression (11). Nevertheless, conflicting results have been

TABLE 3 | Correlation analysis of β -arrestin 2.

Staining	β-arrestin 2	FSHR	LHCGR	GPER	hCGβ		
β-ARRESTIN 2							
CC	1.000	0.183	0.284	0.215	0.360		
p	-	0.029	0.001	0.009	0.000		
n	148	143	146	148	137		
FSHR							
CC	0.183	1.000	0.164	0.214	0.082		
р	0.029	-	0.046	0.009	0.340		
n	143	151	149	148	137		
LHCGR							
CC	0.284	0.164	1.000	0.170	0.200		
p	0.001	0.046	-	0.037	0.018		
n	146	149	154	151	140		
GPER							
CC	0.215	0.214	0.170	1.000	0.114		
р	0.009	0.009	0.037	-	0.179		
n	148	148	151	153	141		
hCGβ							
CC	0.360	0.082	0.200	0.114	1.000		
р	0.000	0.340	0.018	0.179	-		
n	137	137	140	141	142		

cc, correlation coefficient; p, two-tailed significance; n, number of patients.

reported with a positive impact of angiotensin-mediated β arrestin expression in a clinical-genomic dataset from 820 ovarian cancer patients (40). Indicative results may be provided by the analysis of gene expression data stored in public cancer repositories. For instance, The Human Protein Atlas database (https://www.proteinatlas.org; last accession: 03 March 2020) revealed that β -arrestin 2-encoding gene (*ARRB2*) expression is an unfavorable prognostic marker of prostate cancer, although the association is not replicated for ovarian cancer. These data corroborate, at least in part, our finding although they should be considered cautiously, since gene expression levels



p = 0.025). Censoring events have been marked in the graphs.

TABLE 4	Multivariate anal	vsis of the ana	lvzed ovarian	cancer	oatients (n =	156).
	ivianaio anai	y 313 01 this this this	uyzoa ovanan	Guilogi	pationito	// —	100).

Covariate	Coefficient (b _i)	[HR Exp (b _i)]	95% CI		P-value
			Lower	Upper	
Patient's Age (≤60 vs. >60)	0.625	1.869	1.133	3.084	0.014
FIGO (I, II vs. III, IV)	0.813	2.255	1.499	3.393	<0.001
GRADING					
Clear cell, endometrioid, and mucinous (G1–G3)	0.142	1.153	0.749	1.774	0.517
Serous-low grading	-0.695	0.499	0.160	1.562	0.232
Serous-high grading	0.654	1.924	0.765	4.838	0.164
High β-arrestin 2	-0.097	0.907	0.795	1.036	0.152

are not necessarily corresponding to protein levels and the database does not allow to analyze all the specific histological tumor subtypes.

The link between GPCR/ β -arrestins complexes and cancer is an established concept (41) and seems to be result of sustained intracellular signaling occurring upon dysregulation of intracellular β -arrestin protein levels (42). These molecules were associated with drug resistance of breast (43) and lung cancer cells (44), cancer cell migration and invasion (45), tumor progression (46) and metastasis (47), as well as a number of other tumors (48). Thus, β -arrestins were proposed as a target for therapeutic strategies (49). Our data *in vitro* confirm the proliferative role of β -arrestin 2 also in an ovarian cancer cell line, as well as in hGL5 and HEK293 cells. There are converging evidences that β -arrestin 2 depletion leads to decreasing cell viability and/or activating a caspase 3-mediated cell death, at least in HEK293 cells and confirmed in the ovarian cancer cell line A2780. Interestingly, in hGL5 cells, increased β -arrestin 2 expression is linked with upregulation of cell viability, while the depletion of this molecule by siRNA did not result in cell death. This is likely due to the integration of exogenous E6 and E7 oncogenes in the hGL5 cell line genome (23), which served for immortalizing them and, likely, results in increased resistance to caspase 3 activation. On the other hand, these oncogenes encode proteins inhibiting tumor protein 53 (p53) and retinoblastoma (Rb) molecules and interfering with apoptosis and cell cycle blockade. hGL5 have characteristics reflecting epithelial tumor cells, such as fibroblast-like spindle shape and relatively high proliferation rate, a feature depending on β -arrestins functioning (21), as well as in other ovarian cancer cell lines (40). However, these results underline that β-arrestins are modulators of proliferative signals exerted through a molecular signaling module with GPCRs and the extracellular-regulated MAP kinases 1 and



2 (ERK1/2), in a number of cells (50), including ovarian cells (21). Gonadotropin receptors are expressed in ovarian cells and targeted by β -arrestin 2 (51). It is well-known that gonadotropin receptor expression is dysregulated in ovarian cancer (34, 36, 52) as well adrenal tumor (53), although the specific influence of these receptor on carcinogenesis is still not determined (54). One reason for this, may be the bi-directional regulation of pro- and anti-apoptotic signals which depend on FSHR and LHCGR expression levels (55). Interestingly, the depletion of β -arrestin 2 may be linked to increased tumor cell growth and angiogenesis, at least in certain cases, such as lung cancer (56). In this case, the absence of β -arrestin 2 would lead to uncontrolled activation of proliferative signals induced by other GPCRs, e.g., the interleukin 8 receptor beta (CXCR2). Taken together, we could speculate that β arrestins may positively or negatively impact proliferative events, modulating the activity of various GPCRs specifically expressed in the tumor cells.

In correlation analyses, a link between β -arrestin 2 and the G-protein coupled estrogen receptor (GPER) was identified. This receptor is known for rapidly mediating non-genomic

signals induced by estrogens and was found in both healthy and neoplastic human tissue (57, 58). Indeed, previous studies revealed that GPER is related to better overall survival in ovarian cancer patients (34, 59, 60). Since GPER belongs to the GPCRs family, we may suppose that β -arrestin 2 might interact with this membrane estrogen receptor and influence its physiological function. However, this issue must be further investigated because GPER recycling and intracellular trafficking seems to be regulated by mechanisms not involving β -arrestins (61).

Interestingly, we also found an association between β -arrestin 2 and one of the two LHCGR ligands, hCG β . This hormone was shown to be associated with an increased 5-years survival in LHCGR positive/FSHR negative ovarian cancer cases (33). Although this study had limitations related to low specificity of the anti-gonadotropin receptor antibodies employed (62), it suggests that hCG β and its receptor might be linked to survival in these patients. These data would be in line with the relatively high potency of hCG β in inducing LHCGR-mediated intracellular cAMP increase (27), as an effect linked to the steroidogenic potential of the hormone and to proapoptotic effects (24). On the other hand, these data would



be in contrast with the fact that hCG β has been used as a marker of certain tumors, such as the choriocarcinoma (63), which reflects the involvement of β -arrestin 2 in the hCG β -mediated intracellular signaling (29) and suggests that the connection between the two molecules in cancer merits further investigations.

 β -arrestin 2 is associated with a significantly impaired overall survival of ovarian cancer patients. This finding is supported by *in vitro* data demonstrating that β -arrestin 2 upregulates the viability of an ovarian cancer cell line, and transfected HEK293 and hGL5 cells. Reflecting the role of β -arrestins as scaffold proteins linked to the GPCRs activity, correlations between the β -arrestin 2 and FSHR and LHCGR expression was identified ovarian cancer tissue. Taken together, we indicate that β -arrestin 2 may be a promising new target in ovarian cancer so that clinical implications should be further addressed in future research.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of the Ludwig-Maximilians-University, Munich, Germany. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

BC, UJ, MS, LC, and FT: conceptualization. DM, SM, and AB: validation. BC, AP, UJ, and LC: formal analysis. AP, BM, RB,

and SB: investigation. BC, AP, LC, and FT: writing-original draft preparation. UJ, VS, DM, SM, AB, MS, BM, RB, and SB: writing—review and editing. AP, BC, and LC: visualization. UJ, SM, and MS: supervision. All authors have read and agreed to the published version of the manuscript.

FUNDING

MS was a Le Studium Research Fellow, Loire Valley Institute for Advanced Studies, Orléans & Tours, France, INRA—Centre Val de Loire, 37380 Nouzilly, France, receiving funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 665790. This research did not receive any specific grant from any funding agency in the public, commercial, or not-forprofit sector.

REFERENCES

- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2019. *CA Cancer J Clin.* (2019). 69:7–34. doi: 10.3322/caac.21551
- Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. *Obstet Gynecol.* (2012) 120:612–8. doi: 10.1097/AOG.0b013e318264f794
- 3. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d'investigateurs nationaux pour les etudes des cancers de l'Ovaire (GINECO). *Cancer.* (2009) 115:1234–44. doi: 10.1002/cncr. 24149
- Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. *Gynecol Oncol.* (2006) 100:33–7. doi: 10.1016/j.ygyno.2005. 07.123
- Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. *Lancet.* (2001) 357:176– 82. doi: 10.1016/S0140-6736(00)03590-X
- Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad KK. Prognostic factors in patients with stage I epithelial ovarian cancer. *Obstet Gynecol.* (1990) 75:263–73.
- Tomao F, Marchetti C, Romito A, Di Pinto A, Di Donato V, Capri O, et al. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. *Expert Opin Pharmacother*. (2017) 18:1443–55. doi: 10.1080/14656566.2017.1328055
- Kossai M, Leary A, Scoazec JY, Genestie C. Ovarian cancer: a heterogeneous disease. *Pathobiology*. (2018) 85:41–9. doi: 10.1159/000479006
- Shenoy SK, Lefkowitz RJ. β-arrestin-mediated receptor trafficking and signal transduction. *Trends Pharmacol Sci.* (2011) 32:521– 33. doi: 10.1016/j.tips.2011.05.002
- Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA. (2009) 106:8221–6. doi: 10.1073/pnas.08128 79106
- Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. *Proc Natl Acad Sci USA*. (2009) 106:2806–11. doi: 10.1073/pnas.08071 58106

ACKNOWLEDGMENTS

The authors were grateful to Mrs. Christina Kuhn for excellent technical assistance and Professor Gaetano Marverti (University of Modena and Reggio Emilia, Modena, Italy) for providing the A2780 cell line. Authors were grateful to the Italian Ministry of University and Research for supporting the Department of Biomedical, Metabolic, and Neural Sciences (University of Modena and Reggio Emilia, Italy) in the context of the Departments of Excellence Programme.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo. 2020.554733/full#supplementary-material

- Alvarez CJP, Lodeiro M, Theodoropoulou M, Camina JP, Casanueva FF, Pazos Y. Obestatin stimulates Akt signalling in gastric cancer cells through betaarrestin-mediated epidermal growth factor receptor transactivation. *Endocr Relat Cancer*. (2009) 16:599–611. doi: 10.1677/ERC-08-0192
- Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, et al. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst. (2011) 103:317–33. doi: 10.1093/jnci/ djq541
- Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. *Proc Natl Acad Sci USA*. (2006) 103:1492–7. doi: 10.1073/pnas.0510562103
- Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, et al. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. *Cancer Res.* (2008) 68:4097–104. doi: 10.1158/0008-5472.CAN-07-6560
- Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, et al. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. *Mol Cancer Res.* (2009) 7:1064–77. doi: 10.1158/1541-7786.MCR-08-0578
- Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. *EMBO J.* (2002) 21:4037–48. doi: 10.1093/emboj/cdf406
- Rosano L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. *Cancer Res.* (2005) 65:11649–57. doi: 10.1158/0008-5472.CAN-05-2123
- Riccetti L, Klett D, Ayoub MA, Boulo T, Pignatti E, Tagliavini S, et al. Heterogeneous hCG and hMG commercial preparations result in different intracellular signalling but induce a similar long-term progesterone response *in vitro*. *Mol Hum Reprod*. (2017) 23:685–97. doi: 10.1093/molehr/ gax047
- Riccetti L, Sperduti S, Lazzaretti C, Klett D, De Pascali F, Paradiso E, et al. Glycosylation pattern and *in vitro* bioactivity of reference follitropin alfa and biosimilars. *Front Endocrinol.* (2019) 10:503. doi: 10.3389/fendo.2019. 00503
- Casarini L, Reiter E, Simoni, M. β-arrestins regulate gonadotropin receptor-mediated cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling in the hGL5 cell line. *Mol Cell Endocrinol.* (2016) 437:11–21. doi: 10.1016/j.mce.2016. 08.005
- 22. Liu J, Li QX, Wang XJ, Zhang C, Duan YQ, Wang ZY, et al. β -Arrestins promote podocyte injury by inhibition of autophagy in diabetic nephropathy. *Cell Death Dis.* (2016) 7:e2183. doi: 10.1038/cddis. 2016.89

- Rainey WH, Sawetawan C, Shay JW, Michael MD, Mathis JM, Kutteh W, et al. Transformation of human granulosa cells with the E6 and E7 regions of human papillomavirus. *J Clin Endocrinol Metab.* (1994) 78:705– 10. doi: 10.1210/jcem.78.3.8126145
- 24. Casarini L, Riccetti L, De Pascali F, Gilioli L, Marino M, Vecchi E, et al. Estrogen modulates specific life and death signals induced by LH and hCG in human primary granulosa cells *in vitro*. *Int J Mol Sci.* (2017) 18:926. doi: 10.3390/ijms18050926
- Sperduti S, Limoncella S, Lazzaretti C, Paradiso E, Riccetti L, Turchi S, et al. GnRH antagonists produce differential modulation of the signaling pathways mediated by GnRH receptors. *Int J Mol Sci.* (2019) 20:5548. doi: 10.3390/ijms20225548
- 26. Lazzaretti C, Riccetti L, Sperduti S, Anzivino C, Brigante G, De Pascali F, et al. Inferring biallelism of two FSH receptor mutations associated with spontaneous ovarian hyperstimulation syndrome by evaluating FSH, LH and HCG cross-activity. *Reprod Biomed Online.* (2019) 38:816–24. doi: 10.1016/j.rbmo.2018.12.021
- Casarini L, Riccetti L, Limoncella S, Lazzaretti C, Barbagallo F, Pacifico S, et al. Probing the effect of sildenafil on progesterone and testosterone production by an intracellular FRET/BRET combined approach. *Biochemistry*. (2019) 58:799–808. doi: 10.1021/acs.biochem.8b01073
- Brigante G, Riccetti L, Lazzaretti C, Rofrano L, Sperduti S, Poti F, et al. Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotropic cells *in vitro*. *Mol Cell Endocrinol*. (2019) 482:37–44. doi: 10.1016/j.mce.2018.12.005
- Riccetti L, Yvinec R, Klett D, Gallay N, Combarnous Y, Reiter E, et al. Human luteinizing hormone and chorionic gonadotropin display biased agonism at the LH and LH/CG receptors. *Sci Rep.* (2017) 7:940. doi: 10.1038/s41598-017-01078-8
- Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, et al. LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. *PLoS ONE.* (2012) 7:e46682. doi: 10.1371/journal.pone.0046682
- Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. (1983) 65:55–63. doi: 10.1016/0022-1759(83)9 0303-4
- Kabakov AE, Gabai VL. Cell death survival assays. Methods Mol Biol. (2018) 1709:107–27. doi: 10.1007/978-1-4939-7477-1_9
- 33. Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, et al. Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer. *BMC Cancer.* (2012) 12:2. doi: 10.1186/1471-2407-12-2
- 34. Heublein S, Mayr D, Vrekoussis T, Friese K, Hofmann SS, Jeschke U, et al. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients. *PLoS ONE.* (2013) 8:e71791. doi: 10.1371/journal.pone.0 071791
- Heublein S, Vrekoussis T, Mayr D, Friese K, Lenhard M, Jeschke U, et al. Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). *J Ovarian Res.* (2013) 6:6. doi: 10.1186/1757-2215-6-6
- Scholz C, Heublein S, Lenhard M, Friese K, Mayr D, Jeschke U. Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. *BMC Res Notes.* (2012) 5:551. doi: 10.1186/1756-0500-5-551
- Deuster E, Mayr D, Hester A, Kolben T, Zeder-Goss C, Burges A, et al. Correlation of the aryl hydrocarbon receptor with FSHR in ovarian cancer patients. *Int J Mol Sci.* (2019) 20:2862. doi: 10.3390/ijms20122862
- DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Betaarrestins cell signaling. Annu Rev Physiol. (2007) 69:483– 510. doi: 10.1146/annurev.physiol.69.022405.154749
- Kang DS, Tian X, Benovic JL. Role of beta-arrestins and arrestin domaincontaining proteins in G protein-coupled receptor trafficking. *Curr Opin Cell Biol.* (2014) 27:63–71. doi: 10.1016/j.ceb.2013.11.005
- 40. Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, et al. Sensitivity of ovarian cancer cells to acetaminophen reveals biological

pathways that affect patient survival. *Mol Clin Oncol.* (2016) 4:399–404. doi: 10.3892/mco.2016.725

- Suleymanova N, Crudden C, Shibano T, Worrall C, Oprea I, Tica A, et al. Functional antagonism of beta-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes. *Oncogene*. (2017) 36:5734–44. doi: 10.1038/onc.2017.179
- Thomsen ARB, Plouffe B, Cahill TJ III, Shukla AK, Tarrasch JT, Dosey AM, et al. GPCR-G protein-beta-arrestin super-complex mediates sustained G protein signaling. *Cell.* (2016) 166:907–19. doi: 10.1016/j.cell.2016.07.004
- 43. Jing X, Zhang H, Hu J, Su P, Zhang W, Jia M, et al. β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression. *Int J Clin Exp Pathol.* (2015) 8:1354–63.
- 44. Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodriguez ML, et al. CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC. *Cancer Res.* (2019) 79:4439–52. doi: 10.1158/0008-5472.CAN-19-0024
- Rosano L, Bagnato A. New insights into the regulation of the actin cytoskeleton dynamics by GPCR/beta-arrestin in cancer invasion and metastasis. *Int Rev Cell Mol Biol.* (2019) 346:129–55. doi: 10.1016/bs.ircmb.2019.03.002
- Son D, Kim Y, Lim S, Kang HG, Kim DH, Park JW, et al. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer. *Cancer Lett.* (2019) 454:224–33. doi: 10.1016/j.canlet.2019.04.006
- Ji H, Liu N, Li J, Chen D, Luo D, Sun Q, et al. Oxytocin involves in chronic stress-evoked melanoma metastasis via betaarrestin 2-mediated ERK signaling pathway. *Carcinogenesis*. (2019) 40:1395–404. doi: 10.1093/carcin/bgz064
- 48. Song Q, Ji Q, Li Q. The role and mechanism of betaarrestins in cancer invasion and metastasis. *Int J Mol Med*. (2018) 41:631–9. doi: 10.3892/ijmm.2017.3288
- Peterson YK, Luttrell LM. The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. *Pharmacol Rev.* (2017) 69:256– 97. doi: 10.1124/pr.116.013367
- Carmona-Rosas G, Alcantara-Hernandez R, Hernandez-Espinosa DA. Dissecting the signaling features of the multi-protein complex GPCR/beta-arrestin/ERK1/2. Eur J Cell Biol. (2018) 97:349–58. doi: 10.1016/j.ejcb.2018.04.001
- Ayoub MA, Landomiel F, Gallay N, Jegot G, Poupon A, Crepieux P, et al. Assessing gonadotropin receptor function by resonance energy transferbased assays. *Front Endocrinol.* (2015) 6:130. doi: 10.3389/fendo.2015. 00130
- 52. Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, et al. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. *Sci Rep.* (2016) 6:25408. doi: 10.1038/srep 25408
- Bernichtein S, Peltoketo H, Huhtaniemi I. Adrenal hyperplasia and tumours in mice in connection with aberrant pituitary-gonadal function. *Mol Cell Endocrinol.* (2009) 300:164–8. doi: 10.1016/j.mce.2008. 10.005
- Nordhoff V, Gromoll J, Simoni M. Constitutively active mutations of G protein-coupled receptors: the case of the human luteinizing hormone and follicle-stimulating hormone receptors. *Arch Med Res.* (1999) 30:501– 9. doi: 10.1016/S0188-4409(99)00076-4
- Casarini L, Santi D, Simoni M, Poti F. 'Spare' luteinizing hormone receptors: facts and fiction. *Trends Endocrinol Metab.* (2018) 29:208– 17. doi: 10.1016/j.tem.2018.01.007
- Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM. Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol. (2008) 180:5699– 706. doi: 10.4049/jimmunol.180.8.5699
- Jala VR, Radde BN, Haribabu B, Klinge CM. Enhanced expression of Gprotein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer. (2012) 12:624. doi: 10.1186/1471-2407-12-624
- Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. *Breast Cancer Res Treat.* (2011) 128:457– 66. doi: 10.1007/s10549-011-1584-1
- 59. Heublein S, Lenhard M, Vrekoussis T, Schoepfer J, Kuhn C, Friese K, et al. The G-protein-coupled estrogen receptor (GPER) is expressed in

normal human ovaries and is upregulated in ovarian endometriosis and pelvic inflammatory disease involving the ovary. *Reprod Sci.* (2012) 19:1197–204. doi: 10.1177/1933719112446085

- Ignatov T, Modl S, Thulig M, Weissenborn C, Treeck O, Ortmann O, et al. GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian Res. (2013) 6:51. doi: 10.1186/1757-2215-6-51
- Cheng SB, Quinn JA, Graeber CT, Filardo EJ. Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway. *J Biol Chem.* (2011) 286:22441–55. doi: 10.1074/jbc.M111. 224071
- Chrusciel M, Ponikwicka-Tyszko D, Wolczynski S, Huhtaniemi I, Rahman NA. Extragonadal FSHR expression and function-is it real? *Front Endocrinol.* (2019) 10:32. doi: 10.3389/fendo.2019. 00032
- 63. Cole LA, Hartle RJ, Laferla JJ, Ruddon RW. Detection of the free beta subunit of human chorionic gonadotropin (HCG) in cultures of normal and malignant trophoblast cells, pregnancy sera, and sera of patients with choriocarcinoma. *Endocrinology.* (1983) 113:1176–8. doi: 10.1210/endo-113-3-1176

Conflict of Interest: Research support, advisory board, honoraria, and travel expenses from AstraZeneca, Clovis, Medac, MSD, Novartis, PharmaMar, Roche, Sensor Kinesis, Tesaro, Teva have been received by SM and from AstraZeneca, Medac, PharmaMar, Roche, Tesaro/GSK by FT. All above mentioned companies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Czogalla, Partenheimer, Jeschke, von Schönfeldt, Mayr, Mahner, Burges, Simoni, Melli, Benevelli, Bertini, Casarini and Trillsch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.